255 related articles for article (PubMed ID: 1562726)
1. Tissue factor pathway inhibitor: the carboxy-terminus is required for optimal inhibition of factor Xa.
Wesselschmidt R; Likert K; Girard T; Wun TC; Broze GJ
Blood; 1992 Apr; 79(8):2004-10. PubMed ID: 1562726
[TBL] [Abstract][Full Text] [Related]
2. The effect of leukocyte elastase on tissue factor pathway inhibitor.
Higuchi DA; Wun TC; Likert KM; Broze GJ
Blood; 1992 Apr; 79(7):1712-9. PubMed ID: 1558967
[TBL] [Abstract][Full Text] [Related]
3. Kinetics of factor Xa inhibition by tissue factor pathway inhibitor.
Huang ZF; Wun TC; Broze GJ
J Biol Chem; 1993 Dec; 268(36):26950-5. PubMed ID: 8262929
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human extrinsic pathway inhibitor. Production, isolation, and characterization of its inhibitory activity on tissue factor-initiated coagulation reactions.
Pedersen AH; Nordfang O; Norris F; Wiberg FC; Christensen PM; Moeller KB; Meidahl-Pedersen J; Beck TC; Norris K; Hedner U
J Biol Chem; 1990 Oct; 265(28):16786-93. PubMed ID: 2211593
[TBL] [Abstract][Full Text] [Related]
5. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells.
Wun TC; Kretzmer KK; Palmier MO; Day KC; Huang MD; Welsch DJ; Lewis C; Wolfe RA; Zobel JF; Lange GW
Thromb Haemost; 1992 Jul; 68(1):54-9. PubMed ID: 1325078
[TBL] [Abstract][Full Text] [Related]
6. Effect of heparin on the inhibition of factor Xa by tissue factor pathway inhibitor: a segment, Gly212-Phe243, of the third Kunitz domain is a heparin-binding site.
Enjyoji K; Miyata T; Kamikubo Y; Kato H
Biochemistry; 1995 May; 34(17):5725-35. PubMed ID: 7727433
[TBL] [Abstract][Full Text] [Related]
7. Structural requirements for tissue factor pathway inhibitor interactions with factor Xa and heparin.
Wesselschmidt R; Likert K; Huang Z; MacPhail L; Broze GJ
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):661-9. PubMed ID: 8292716
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor.
Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W
Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184
[TBL] [Abstract][Full Text] [Related]
9. Activation of factor X and its regulation by tissue factor pathway inhibitor in small-diameter capillaries lined with human endothelial cells.
Lindhout T; Blezer R; Schoen P; Nordfang O; Reutelingsperger C; Hemker HC
Blood; 1992 Jun; 79(11):2909-16. PubMed ID: 1586738
[TBL] [Abstract][Full Text] [Related]
10. Tissue factor residues Lys165 and Lys166 are essential for rapid formation of the quaternary complex of tissue factor.VIIa with Xa.tissue factor pathway inhibitor.
Rao LV; Ruf W
Biochemistry; 1995 Aug; 34(34):10867-71. PubMed ID: 7662667
[TBL] [Abstract][Full Text] [Related]
11. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor (TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa-tissue factor complexes on cell surfaces.
Hamamoto T; Yamamoto M; Nordfang O; Petersen JG; Foster DC; Kisiel W
J Biol Chem; 1993 Apr; 268(12):8704-10. PubMed ID: 8473315
[TBL] [Abstract][Full Text] [Related]
12. Structural requirements for TFPI-mediated inhibition of neointimal thickening after balloon injury in the rat.
Han X; Girard TJ; Baum P; Abendschein DR; Broze GJ
Arterioscler Thromb Vasc Biol; 1999 Oct; 19(10):2563-7. PubMed ID: 10521388
[TBL] [Abstract][Full Text] [Related]
13. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin.
Jesty J; Wun TC; Lorenz A
Biochemistry; 1994 Oct; 33(42):12686-94. PubMed ID: 7918495
[TBL] [Abstract][Full Text] [Related]
14. Pharmacological profiling of recombinant tissue factor pathway inhibitor.
Jeske W; Hoppensteadt D; Callas D; Koza MJ; Fareed J
Semin Thromb Hemost; 1996; 22(2):213-9. PubMed ID: 8807720
[TBL] [Abstract][Full Text] [Related]
15. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma.
Novotny WF; Girard TJ; Miletich JP; Broze GJ
J Biol Chem; 1989 Nov; 264(31):18832-7. PubMed ID: 2553722
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein.
Girard TJ; MacPhail LA; Likert KM; Novotny WF; Miletich JP; Broze GJ
Science; 1990 Jun; 248(4961):1421-4. PubMed ID: 1972598
[TBL] [Abstract][Full Text] [Related]
17. The effect of heparin on the regulation of factor VIIa-tissue factor activity by tissue factor pathway inhibitor.
Hamamoto T; Kisiel W
Blood Coagul Fibrinolysis; 1996 Jun; 7(4):470-6. PubMed ID: 8840000
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of tissue factor:factor VIIa-catalyzed factor IX and factor X activation by TFPI and TFPI constructs.
Peraramelli S; Thomassen S; Heinzmann A; Rosing J; Hackeng TM; Hartmann R; Scheiflinger F; Dockal M
J Thromb Haemost; 2014 Nov; 12(11):1826-37. PubMed ID: 25163770
[TBL] [Abstract][Full Text] [Related]
19. The Kunitz 1 and Kunitz 3 domains of tissue factor pathway inhibitor are required for efficient inhibition of factor Xa.
Peraramelli S; Suylen DP; Rosing J; Hackeng TM
Thromb Haemost; 2012 Aug; 108(2):266-76. PubMed ID: 22627666
[TBL] [Abstract][Full Text] [Related]
20. The C-terminus of tissue factor pathway inhibitor is essential to its anticoagulant activity.
Nordfang O; Bjørn SE; Valentin S; Nielsen LS; Wildgoose P; Beck TC; Hedner U
Biochemistry; 1991 Oct; 30(43):10371-6. PubMed ID: 1931960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
